ArticleF&S reports2024
Fertility journey of a patient with McCune-Albright syndrome associated with bilateral ovarian involvement.
Article in F&S reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To report a patient with McCune-Albright syndrome (MAS) with bilateral ovarian involvement who had achieved a pregnancy through in vitro fertilization (IVF). Design: Case report. Setting: Academic fertility center. Patients: A 33-year-old female with McCune-Albright syndrome who presented with primary infertility because of ovulatory dysfunction secondary to excessive secretion of growth hormone in addition to autonomous estrogen secretion by her ovaries. Exposure: In vitro fertilization and near-normalization of insulin-like growth factor-1 (IGF-1) using somatostatin analogue lanreotide. Main Outcome Measures: Reproductive outcomes after medical treatment for MAS-associated anovulatory infertility involving bilateral MAS ovarian involvement and growth hormone excess. Results: Spontaneous ovulation was resumed in this patient using lanreotide which regulated IGF-1 levels after unsuccessful ovulation induction with letrozole. Despite documented ovulation, she failed to conceive and subsequently, underwent an IVF cycle using an antagonist cycle with recombinant follicular stimulating hormone and recombinant luteinizing hormone stimulation. A total of 13 oocytes were retrieved and three good quality blastocysts were cryopreserved. Two frozen embryo transfer cycles were completed and she achieved a pregnancy, which unfortunately ended in an incomplete miscarriage. Conclusions: Through IVF and near-normalization of IGF-1 using lanreotide, pregnancy was achieved in a patient with MAS who had achieved good ovarian stimulation despite a history of bilateral ovarian involvement and associated hyperfunctioning endocrinopathies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.